RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Michele Carbone to Asbestos

This is a "connection" page, showing publications Michele Carbone has written about Asbestos.
Connection Strength

9.272
  1. Carbone M, Minaai M, Takinishi Y, Pagano I, Yang H. Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma. J Transl Med. 2023 10 25; 21(1):749.
    View in: PubMed
    Score: 0.891
  2. Carbone M, Yang H, Pass HI, Taioli E. Did the Ban on Asbestos Reduce the Incidence of Mesothelioma? J Thorac Oncol. 2023 06; 18(6):694-697.
    View in: PubMed
    Score: 0.867
  3. Yang H, Gaudino G, Bardelli F, Carbone M. Does the Amount of Asbestos Exposure Influence Prognosis? J Thorac Oncol. 2022 08; 17(8):949-952.
    View in: PubMed
    Score: 0.818
  4. Novelli F, Bononi A, Wang Q, Bai F, Patergnani S, Kricek F, Haglund E, Suarez JS, Tanji M, Xu R, Takanishi Y, Minaai M, Pastorino S, Morris P, Sakamoto G, Pass HI, Barbour H, Gaudino G, Giorgi C, Pinton P, Onuchic JN, Yang H, Carbone M. BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene ? environment interaction with asbestos. Proc Natl Acad Sci U S A. 2021 11 30; 118(48).
    View in: PubMed
    Score: 0.781
  5. Mao W, Zhang X, Guo Z, Gao Z, Pass HI, Yang H, Carbone M. Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China. JAMA Oncol. 2017 04 01; 3(4):562-564.
    View in: PubMed
    Score: 0.565
  6. Baumann F, Buck BJ, Metcalf RV, McLaurin BT, Merkler D, Carbone M. Reply to "No Increased Risk for Mesothelioma in Relation to Natural-Occurring Asbestos in Southern Nevada". J Thorac Oncol. 2015 Jul; 10(7):e64-5.
    View in: PubMed
    Score: 0.501
  7. Baumann F, Buck BJ, Metcalf RV, McLaurin BT, Merkler DJ, Carbone M. The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada. J Thorac Oncol. 2015 May; 10(5):731-737.
    View in: PubMed
    Score: 0.495
  8. Baumann F, Ambrosi JP, Carbone M. Asbestos is not just asbestos: an unrecognised health hazard. Lancet Oncol. 2013 Jun; 14(7):576-8.
    View in: PubMed
    Score: 0.434
  9. Carbone M, Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 2012 Feb 01; 18(3):598-604.
    View in: PubMed
    Score: 0.389
  10. Yang H, Nasu M, Strianese O, Rivera Z, Luecke L, Carbone M. The legacy of "miracle mineral": asbestos and cancer. Hawaii Med J. 2009 Jan-Feb; 68(1):18-20.
    View in: PubMed
    Score: 0.319
  11. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, Franzoso G, Carbone M. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A. 2006 Jul 05; 103(27):10397-10402.
    View in: PubMed
    Score: 0.268
  12. Carbone M, Bedrossian CW. The pathogenesis of mesothelioma. Semin Diagn Pathol. 2006 Feb; 23(1):56-60.
    View in: PubMed
    Score: 0.261
  13. Tanvetyanon T, Elmishad AG, Carbone M. Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link? Anticancer Res. 2005 Jan-Feb; 25(1B):429-33.
    View in: PubMed
    Score: 0.242
  14. Novelli F, Yoshikawa Y, Vitto VAM, Modesti L, Minaai M, Pastorino S, Emi M, Kim JH, Kricek F, Bai F, Onuchic JN, Bononi A, Suarez JS, Tanji M, Favaron C, Zolondick AA, Xu R, Takanishi Y, Wang Z, Sakamoto G, Gaudino G, Grzymski J, Grosso F, Schrump DS, Pass HI, Atanesyan L, Smout J, Savola S, Sarin KY, Abolhassani H, Hammarstr?m L, Pan-Hammarstr?m Q, Giorgi C, Pinton P, Yang H, Carbone M. Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling. Proc Natl Acad Sci U S A. 2024 Jul 16; 121(29):e2405231121.
    View in: PubMed
    Score: 0.234
  15. Suarez JS, Novelli F, Goto K, Ehara M, Steele M, Kim JH, Zolondick AA, Xue J, Xu R, Saito M, Pastorino S, Minaai M, Takanishi Y, Emi M, Pagano I, Wakeham A, Berger T, Pass HI, Gaudino G, Mak TW, Carbone M, Yang H. HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma. Proc Natl Acad Sci U S A. 2023 09 26; 120(39):e2307999120.
    View in: PubMed
    Score: 0.221
  16. Xue J, Patergnani S, Giorgi C, Suarez J, Goto K, Bononi A, Tanji M, Novelli F, Pastorino S, Xu R, Caroccia N, Dogan AU, Pass HI, Tognon M, Pinton P, Gaudino G, Mak TW, Carbone M, Yang H. Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. Proc Natl Acad Sci U S A. 2020 10 13; 117(41):25543-25552.
    View in: PubMed
    Score: 0.180
  17. Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019 09; 69(5):402-429.
    View in: PubMed
    Score: 0.165
  18. Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature. 2017 06 22; 546(7659):549-553.
    View in: PubMed
    Score: 0.143
  19. Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S, Goparaju CM, Prokrym K, Canino C, Pass HI, Carbone M, Yang H. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Clin Cancer Res. 2016 06 15; 22(12):3087-96.
    View in: PubMed
    Score: 0.130
  20. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012 Oct 11; 367(15):1417-27.
    View in: PubMed
    Score: 0.104
  21. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011 Aug 28; 43(10):1022-5.
    View in: PubMed
    Score: 0.096
  22. Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, Gaudino G, Jube S, Kanodia S, Partridge CR, Pass HI, Rivera ZS, Steele I, Tuncer M, Way S, Yang H, Miller A. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A. 2011 Aug 16; 108(33):13618-23.
    View in: PubMed
    Score: 0.095
  23. Altomare DA, Menges CW, Xu J, Pei J, Zhang L, Tadevosyan A, Neumann-Domer E, Liu Z, Carbone M, Chudoba I, Klein-Szanto AJ, Testa JR. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One. 2011 Apr 19; 6(4):e18828.
    View in: PubMed
    Score: 0.094
  24. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI, Bianchi ME, Carbone M. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12611-6.
    View in: PubMed
    Score: 0.088
  25. Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009; 21(2):97-104.
    View in: PubMed
    Score: 0.080
  26. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008 Jun; 9(2-3):147-57.
    View in: PubMed
    Score: 0.078
  27. Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med. 2008 Jul; 14(4):316-21.
    View in: PubMed
    Score: 0.077
  28. Carbone M, Strianese O, Theos K, Yang H. Mesothelioma. Hawaii Med J. 2007 Feb; 66(2):48-50.
    View in: PubMed
    Score: 0.070
  29. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, Mossman BT. Cellular and molecular parameters of mesothelioma. J Cell Biochem. 2006 Jul 01; 98(4):723-34.
    View in: PubMed
    Score: 0.067
  30. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005 Oct 13; 353(15):1564-73.
    View in: PubMed
    Score: 0.064
  31. Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer. 2004 May-Jun; 28(3):93-174.
    View in: PubMed
    Score: 0.058
  32. Carbone M, Rdzanek MA. Pathogenesis of malignant mesothelioma. Clin Lung Cancer. 2004 Apr; 5 Suppl 2:S46-50.
    View in: PubMed
    Score: 0.057
  33. Gazdar AF, Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer. 2003 Nov; 5(3):177-81.
    View in: PubMed
    Score: 0.056
  34. Powers A, Carbone M. The role of environmental carcinogens, viruses and genetic predisposition in the pathogenesis of mesothelioma. Cancer Biol Ther. 2002 Jul-Aug; 1(4):348-53.
    View in: PubMed
    Score: 0.051
  35. Emri S, Demir A, Dogan M, Akay H, Bozkurt B, Carbone M, Baris I. Lung diseases due to environmental exposures to erionite and asbestos in Turkey. Toxicol Lett. 2002 Feb 28; 127(1-3):251-7.
    View in: PubMed
    Score: 0.050
  36. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002 Feb; 29(1):2-17.
    View in: PubMed
    Score: 0.049
  37. Pass HI, Alimi M, Carbone M, Yang H, Goparaju CM. Mesothelioma Biomarkers: Discovery in Search of Validation. Thorac Surg Clin. 2020 Nov; 30(4):395-423.
    View in: PubMed
    Score: 0.045
  38. Ostroff RM, Mehan MR, Stewart A, Ayers D, Brody EN, Williams SA, Levin S, Black B, Harbut M, Carbone M, Goparaju C, Pass HI. Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One. 2012; 7(10):e46091.
    View in: PubMed
    Score: 0.026
  39. Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S, Aharonov R. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010 Mar 01; 70(5):1916-24.
    View in: PubMed
    Score: 0.022
  40. Shukla A, Bosenberg MW, MacPherson MB, Butnor KJ, Heintz NH, Pass HI, Carbone M, Testa JR, Mossman BT. Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. Am J Pathol. 2009 Nov; 175(5):2197-206.
    View in: PubMed
    Score: 0.021
  41. Bertino P, Carbone M, Pass H. Chemotherapy of malignant pleural mesothelioma. Expert Opin Pharmacother. 2009 Jan; 10(1):99-107.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support